Process monitoring of polysaccharide deketalization for vaccine bioconjugation development using in situ analytical methodology.
PAT
PCV
Pharmaceuticals
Pneumococcal conjugate vaccine
Process analytical technology
Real time analysis
Spectroscopy
Vaccine process development
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
05 Feb 2022
05 Feb 2022
Historique:
received:
16
09
2021
revised:
08
12
2021
accepted:
09
12
2021
pubmed:
21
12
2021
medline:
12
1
2022
entrez:
20
12
2021
Statut:
ppublish
Résumé
Pneumococcal conjugate vaccines (PCVs) are formed by bioconjugation of a carrier protein to the purified capsular polysaccharide (Ps) from multiple serological strains of Streptococcus pneumoniae. The associated bioconjugation chemistry relies on initial selective modifications to the Ps backbone structure. Among these modifications, removal of a ketal functional group, termed deketalization, is one that is important for pharmaceutical PCV production. Herein, we report a process monitoring investigation into the deketalization of a polysaccharide relevant to PCV process development. We have applied process analytical technology (PAT) for in situ process monitoring to study the deketalization reaction in real time. We find that in situ FTIR spectroscopy elucidates multiple classes of reaction kinetics, one of which correlates strongly with the deketalization reaction of interest. This PAT approach to real time reaction monitoring offers the possibility of improved process monitoring in the pharmaceutical production of PCVs. To our knowledge, this report represents the first PAT investigation into Ps deketalization. Our findings suggest that broader application of PAT to the chemical modifications associated with PCV bioconjugation, as well as other pharmaceutically relevant bioconjugation processes, carries the power to enhance process understanding, control, and efficiency through real time process monitoring.
Identifiants
pubmed: 34929570
pii: S0731-7085(21)00644-0
doi: 10.1016/j.jpba.2021.114533
pii:
doi:
Substances chimiques
Carrier Proteins
0
Pneumococcal Vaccines
0
Polysaccharides
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114533Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.